Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.
Journal
Nature nanotechnology
ISSN: 1748-3395
Titre abrégé: Nat Nanotechnol
Pays: England
ID NLM: 101283273
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
received:
25
09
2021
accepted:
24
06
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
aheadofprint
Résumé
Regulating innate immunity is an emerging approach to improve cancer immunotherapy. Such regulation requires engaging myeloid cells by delivering immunomodulatory compounds to hematopoietic organs, including the spleen. Here we present a polymersome-based nanocarrier with splenic avidity and propensity for red pulp myeloid cell uptake. We characterized the in vivo behaviour of four chemically identical yet topologically different polymersomes by in vivo positron emission tomography imaging and innovative flow and mass cytometry techniques. Upon intravenous administration, relatively large and spherical polymersomes accumulated rapidly in the spleen and efficiently targeted myeloid cells in the splenic red pulp. When loaded with β-glucan, intravenously administered polymersomes significantly reduced tumour growth in a mouse melanoma model. We initiated our nanotherapeutic's clinical translation with a biodistribution study in non-human primates, which revealed that the platform's splenic avidity is preserved across species.
Identifiants
pubmed: 39085390
doi: 10.1038/s41565-024-01727-w
pii: 10.1038/s41565-024-01727-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : ERC Advanced Grant (Artisym 694120)
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : ERC Advanced Grant (#833247)
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : ERC, Smart Nanoparticles, 101089009
Organisme : Azrieli Foundation
ID : postdoctoral fellowship
Organisme : Rothschild Caesarea Foundation
ID : Baroness Ariane de Rothschild Women Doctoral Program
Informations de copyright
© 2024. The Author(s).
Références
Theobald, M. (ed). Current Immunotherapeutic Strategies in Cancer (Springer, 2020).
Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
pubmed: 33811120
doi: 10.1158/2159-8290.CD-20-1680
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
pubmed: 27339708
doi: 10.1038/nrc.2016.54
Jung, K. et al. Ly6C
pubmed: 28691930
pmcid: 5531423
doi: 10.1172/JCI93182
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899–919 (2021).
pubmed: 33686237
doi: 10.1038/s41573-021-00155-y
Wu, C. et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J. Clin. Invest. 128, 3425–3438 (2018).
pubmed: 29771686
pmcid: 6063469
doi: 10.1172/JCI97973
Demaria, O. et al. Harnessing innate immunity in cancer therapy. Nature 574, 45–56 (2019).
pubmed: 31578484
doi: 10.1038/s41586-019-1593-5
Priem, B. et al. Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183, 786–801.e19 (2020).
pubmed: 33125893
pmcid: 8074872
doi: 10.1016/j.cell.2020.09.059
Rabold, K. et al. Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma. Nat. Commun. 13, 6149 (2022).
pubmed: 36257966
pmcid: 9579179
doi: 10.1038/s41467-022-33907-4
Lewis, S. M., Williams, A. & Eisenbarth, S. C. Structure and function of the immune system in the spleen. Sci. Immunol. 4, eaau6085 (2019).
pubmed: 30824527
pmcid: 6495537
doi: 10.1126/sciimmunol.aau6085
Bronte, V. & Pittet, M. J. The spleen in local and systemic regulation of immunity. Immunity 39, 806–818 (2013).
pubmed: 24238338
pmcid: 3912742
doi: 10.1016/j.immuni.2013.10.010
Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612–616 (2009).
pubmed: 19644120
pmcid: 2803111
doi: 10.1126/science.1175202
Jordan, K. R. et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol. Immunother. 66, 503–513 (2017).
pubmed: 28108766
pmcid: 5580403
doi: 10.1007/s00262-016-1953-z
Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345–359 (2021).
pubmed: 33837297
pmcid: 8034277
doi: 10.1038/s41568-021-00347-z
Wu, C., Hua, Q. & Zheng, L. Generation of myeloid cells in cancer: the spleen matters. Front. Immunol. 11, 1–13 (2020).
Wang, X. & Li, Y. The disruption of hematopoiesis in tumor progression. Blood Sci. 1, 88–91 (2019).
pubmed: 35402791
pmcid: 8975043
doi: 10.1097/BS9.0000000000000001
van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14, 1007–1017 (2019).
pubmed: 31695150
pmcid: 7227032
doi: 10.1038/s41565-019-0567-y
Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553–566 (2019).
pubmed: 30967658
pmcid: 7069501
doi: 10.1038/s41573-019-0025-4
Bekkering, S. et al. In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 23, 926–933 (2016).
pubmed: 27733422
pmcid: 5139603
doi: 10.1128/CVI.00349-16
Bekkering, S. et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell 172, 135–146.e9 (2018).
pubmed: 29328908
doi: 10.1016/j.cell.2017.11.025
Arts, R. J. W. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807–819 (2016).
pubmed: 27866838
pmcid: 5742541
doi: 10.1016/j.cmet.2016.10.008
Domínguez-Andrés, J. et al. In vitro induction of trained immunity in adherent human monocytes. STAR Protoc. 2, 100365 (2021).
pubmed: 33718890
pmcid: 7921712
doi: 10.1016/j.xpro.2021.100365
Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388 (2020).
pubmed: 32132681
pmcid: 7186935
doi: 10.1038/s41577-020-0285-6
Kalafati, L. et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183, 771–785.e12 (2020).
pubmed: 33125892
pmcid: 7599076
doi: 10.1016/j.cell.2020.09.058
Geller, A. E. et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat. Commun. 13, 759 (2022).
pubmed: 35140221
pmcid: 8828725
doi: 10.1038/s41467-022-28407-4
Ding, C. et al. Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis. Nat. Immunol. 24, 239–254 (2023).
pubmed: 36604547
pmcid: 10636755
doi: 10.1038/s41590-022-01388-8
Mata-Martínez, P., Bergón-Gutiérrez, M. & del Fresno, C. Dectin-1 signaling update: new perspectives for trained immunity. Front. Immunol. 13, 1–18 (2022).
doi: 10.3389/fimmu.2022.812148
Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).
pubmed: 32005979
pmcid: 7536618
doi: 10.1038/s41577-019-0269-6
Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).
pubmed: 30622344
pmcid: 6410566
doi: 10.1038/s41573-018-0006-z
Shi, Y. & Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 52, 1543–1554 (2019).
pubmed: 31120725
pmcid: 7115879
doi: 10.1021/acs.accounts.9b00148
van Leent, M. M. T. et al. A modular approach toward producing nanotherapeutics targeting the innate immune system. Sci. Adv. 7, 1–13 (2021).
Nam, J. et al. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4, 398–414 (2019).
doi: 10.1038/s41578-019-0108-1
Schudel, A. et al. Programmable multistage drug delivery to lymph nodes. Nat. Nanotechnol. 15, 491–499 (2020).
pubmed: 32523099
pmcid: 7305972
doi: 10.1038/s41565-020-0679-4
Yi, S. et al. Surface engineered polymersomes for enhanced modulation of dendritic cells during cardiovascular immunotherapy. Adv. Funct. Mater. 29, 1904399 (2019).
pubmed: 34335131
pmcid: 8320590
doi: 10.1002/adfm.201904399
Sofias, A. M., Combes, F., Koschmieder, S., Storm, G. & Lammers, T. A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discov. Today 26, 1482–1489 (2021).
pubmed: 33617793
pmcid: 7611945
doi: 10.1016/j.drudis.2021.02.017
Lameijer, M. et al. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat. Biomed. Eng. 2, 279–292 (2018).
pubmed: 30936448
pmcid: 6447057
doi: 10.1038/s41551-018-0221-2
Binderup, T. et al. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci. Transl. Med. 11, eaaw7736 (2019).
pubmed: 31434756
pmcid: 7328283
doi: 10.1126/scitranslmed.aaw7736
Scheerstra, J. F., Wauters, A. C., Tel, J., Abdelmohsen, L. K. E. A. & van Hest, J. C. M. Polymersomes as a potential platform for cancer immunotherapy. Mater. Today Adv. 13, 100203 (2022).
doi: 10.1016/j.mtadv.2021.100203
Abdelmohsen, L. K. E. A. et al. Formation of well-defined, functional nanotubes via osmotically induced shape transformation of biodegradable polymersomes. J. Am. Chem. Soc. 138, 9353–9356 (2016).
pubmed: 27374777
pmcid: 4974604
doi: 10.1021/jacs.6b03984
Wauters, A. C. et al. Development of morphologically discrete PEG-PDLLA nanotubes for precision nanomedicine. Biomacromolecules 20, 177–183 (2019).
pubmed: 30265794
doi: 10.1021/acs.biomac.8b01245
Wibroe, P. P. et al. Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nat. Nanotechnol. 12, 589–594 (2017).
pubmed: 28396605
doi: 10.1038/nnano.2017.47
Yi, S. et al. Tailoring nanostructure morphology for enhanced targeting of dendritic cells in atherosclerosis. ACS Nano 10, 11290–11303 (2016).
pubmed: 27935698
pmcid: 5418862
doi: 10.1021/acsnano.6b06451
Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249–255 (2007).
pubmed: 18654271
pmcid: 2740330
doi: 10.1038/nnano.2007.70
Wauters, A. C. et al. Artificial antigen-presenting cell topology dictates T cell activation. ACS Nano 16, 15072–15085 (2022).
pubmed: 35969506
pmcid: 9527792
doi: 10.1021/acsnano.2c06211
Pérez-Medina, C. et al. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J. Nucl. Med. 55, 1706–1711 (2014).
pubmed: 25060196
doi: 10.2967/jnumed.114.141861
Pérez-Medina, C., Teunissen, A. J. P., Kluza, E., Mulder, W. J. M. & van der Meel, R. Nuclear imaging approaches facilitating nanomedicine translation. Adv. Drug Deliv. Rev. 154–155, 123–141 (2020).
pubmed: 32721459
doi: 10.1016/j.addr.2020.07.017
Song, K. et al. Laminarin promotes anti-cancer immunity by the maturation of dendritic cells. Oncotarget 8, 38554–38567 (2017).
pubmed: 28423736
pmcid: 5503553
doi: 10.18632/oncotarget.16170
Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet 398, 1002–1014 (2021).
pubmed: 34509219
doi: 10.1016/S0140-6736(21)01206-X
Koo, B.-S. et al. Reference values of hematological and biochemical parameters in young-adult cynomolgus monkey (Macaca fascicularis) and rhesus monkey (Macaca mulatta) anesthetized with ketamine hydrochloride. Lab. Anim. Res. 35, 7 (2019).
pubmed: 32257895
pmcid: 7081622
doi: 10.1186/s42826-019-0006-0